Description: Mydecine Innovations Group Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. Its lead product drug candidates include MYCO-005. The company also develops MYCO-006 and MYCO-007. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
Home Page: www.mydecine.com
1075 West Georgia Street
Vancouver,
BC
V6E 3C9
Canada
Phone:
604 687 2038
Officers
| Name | Title |
|---|---|
| Mr. David Joshua Bartch | Co-Founder, CEO, President & Chairman of the Board |
| Mr. Robert Roscow M.A. | Co-Founder, Chief Scientific Officer & Director |
| Mr. Damon Michaels | Co-Founder & COO |
| Mr. John Charles Ross CA, CPA, M.B.A. | CFO & Corporate Secretary |
| Mr. Sanford M. Stein | Chief Compliance Officer & General Counsel |
| Dr. Rakesh Jetly FRCPC, M.D. | Chief Medical Officer |
| Morgan Kervitsky | Director of Marketing |
| Mr. Michel Rudolphie | President of the European Operations |
| Mr. William Cook | Interim CEO & Technical Director of Mindleap Health Inc. |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 528.4778 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |